Immunotherapy transforms cancer treatment.
作者信息
Zaidi Neeha, Jaffee Elizabeth M
出版信息
J Clin Invest. 2019 Jan 2;129(1):46-47. doi: 10.1172/JCI126046. Epub 2018 Dec 3.
Abstract
摘要
相似文献
1
Immunotherapy transforms cancer treatment.免疫疗法改变了癌症治疗方式。
J Clin Invest. 2019 Jan 2;129(1):46-47. doi: 10.1172/JCI126046. Epub 2018 Dec 3.
2
Immunotherapy: hype and hope.免疫疗法：炒作与希望。
Lancet Oncol. 2018 Jul;19(7):845. doi: 10.1016/S1470-2045(18)30317-6. Epub 2018 Jun 29.
3
Professor Jon Wigginton: where we are standing in immunotherapy.乔恩·威金顿教授：我们在免疫疗法领域的进展。
Chin Clin Oncol. 2015 Mar;4(1):16. doi: 10.3978/j.issn.2304-3865.2014.01.01.
4
A new era for cancer immunotherapy based on the genes that encode cancer antigens.基于编码癌症抗原的基因的癌症免疫疗法新时代。
Immunity. 1999 Mar;10(3):281-7. doi: 10.1016/s1074-7613(00)80028-x.
5
Overview: immunotherapy for cancer--is it time for the kitchen sink?概述：癌症免疫疗法——是时候动用一切手段了吗？
Curr Opin Investig Drugs. 2002 Jan;3(1):130-1.
6
Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment.十年回顾——癌症免疫疗法：步入癌症治疗主流
Nat Rev Clin Oncol. 2014 Nov;11(11):630-2. doi: 10.1038/nrclinonc.2014.174. Epub 2014 Oct 14.
7
"Immunotherapy of cancer: present status and future promise": Danish Cancer Society Symposium, Copenhagen, Denmark, 23rd-25th September 2013.“癌症免疫疗法：现状与未来前景”：丹麦癌症协会研讨会，丹麦哥本哈根，2013年9月23日至25日
Cancer Immunol Immunother. 2014 Sep;63(9):985-9. doi: 10.1007/s00262-014-1585-0. Epub 2014 Jul 24.
8
The case for cancer immunotherapy.癌症免疫疗法的情况。
Drug Discov Today. 2003 Jun 15;8(12):530-1. doi: 10.1016/s1359-6446(03)02727-2.
9
Cancer immunotherapy in 2017: The breakthrough of the microbiota.2017年癌症免疫疗法：微生物群的突破。
Nat Rev Immunol. 2018 Jan 30;18(2):87-88. doi: 10.1038/nri.2018.4.
10
[Unleashing NK cell signaling to improve cancer immunotherapy].释放自然杀伤细胞信号以改善癌症免疫疗法
Med Sci (Paris). 2020 Oct;36 Hors série n° 1:50-55. doi: 10.1051/medsci/2020195. Epub 2020 Oct 14.
引用本文的文献
1
Innovative Peptide Therapeutics in the Pipeline: Transforming Cancer Detection and Treatment.正在研发的创新肽疗法：变革癌症检测与治疗
Int J Mol Sci. 2025 Jul 16;26(14):6815. doi: 10.3390/ijms26146815.
2
Dual regulation of the cGAS-STING pathway: new targets and challenges for subtype-specific immunotherapy in breast cancer.cGAS-STING通路的双重调控：乳腺癌亚型特异性免疫治疗的新靶点与挑战
Front Oncol. 2025 Jun 10;15:1619097. doi: 10.3389/fonc.2025.1619097. eCollection 2025.
3
Endothelial Per-Arnt-Sim domain-containing protein 1 expression is correlated with poor prognosis and promotes invasion and metastasis in gastric cancer.内皮细胞含Per-Arnt-Sim结构域蛋白1的表达与胃癌预后不良相关，并促进胃癌的侵袭和转移。
World J Gastrointest Oncol. 2025 Jun 15;17(6):105213. doi: 10.4251/wjgo.v17.i6.105213.
4
PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma.PARP抑制剂在高级别浆液性输卵管卵巢癌的不同遗传背景中对免疫反应有不同调节作用。
Cancer Res Commun. 2025 Feb 1;5(2):339-348. doi: 10.1158/2767-9764.CRC-24-0515.
5
Pembrolizumab Leads to Complete Response in an HIV Patient With a Solid Tumor and a Cluster of Differentiation 4 (CD4) Count Less Than 100.帕博利珠单抗使一名实体瘤且分化簇4（CD4）计数低于100的HIV患者获得完全缓解。
Cureus. 2024 Dec 13;16(12):e75680. doi: 10.7759/cureus.75680. eCollection 2024 Dec.
6
The pros and cons of probiotic use in pediatric oncology patients following treatment for acute lymphoblastic leukemia.益生菌用于急性淋巴细胞白血病治疗后的儿科肿瘤患者的利弊。
Front Pediatr. 2024 Oct 22;12:1427185. doi: 10.3389/fped.2024.1427185. eCollection 2024.
7
Quantifying collagen reorganization during immunotherapy in murine melanoma with second harmonic generation imaging.利用二次谐波成像对小鼠黑色素瘤免疫治疗过程中的胶原蛋白重组进行定量分析。
Biophotonics Discov. 2024 May;1(1). doi: 10.1117/1.bios.1.1.015004. Epub 2024 May 20.
8
Role of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy.缺氧诱导因子-1α（HIF-1α）在肿瘤对放疗和化疗反应中的作用
Cancer Res Treat. 2025 Jan;57(1):1-10. doi: 10.4143/crt.2024.255. Epub 2024 Jun 5.
9
Reprogramming T-cell metabolism to enhance adoptive cell therapies.重编程 T 细胞代谢以增强过继细胞疗法。
Int Immunol. 2024 Apr 27;36(6):261-278. doi: 10.1093/intimm/dxae007.
10
A Review of 10-Year Survivability of Immunotherapy in the Management of Colon Cancer.免疫疗法治疗结肠癌的10年生存率综述
Cureus. 2023 Aug 9;15(8):e43189. doi: 10.7759/cureus.43189. eCollection 2023 Aug.
本文引用的文献
1
Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.基于 STING 的新抗原靶向疫苗与检查点调节剂联合增强了小鼠胰腺癌的抗肿瘤免疫。
JCI Insight. 2018 Oct 18;3(20):122857. doi: 10.1172/jci.insight.122857.
2
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.肿瘤突变负荷与对PD-1抑制的反应率
N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.
3
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的总生存期
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
4
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
5
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.细胞毒性T淋巴细胞相关抗原4抗体阻断在既往接种过疫苗的转移性黑色素瘤和卵巢癌患者中的生物活性。
Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7. doi: 10.1073/pnas.0830997100. Epub 2003 Apr 7.
6
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.肿瘤细胞上的PD-L1在逃避宿主免疫系统及通过阻断PD-L1进行肿瘤免疫治疗中的作用。
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7. doi: 10.1073/pnas.192461099. Epub 2002 Sep 6.
7
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.程序性死亡配体2（PD-L2）是程序性死亡受体1（PD-1）的第二种配体，可抑制T细胞活化。
Nat Immunol. 2001 Mar;2(3):261-8. doi: 10.1038/85330.
8
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.一种新型B7家族成员与PD-1免疫抑制受体的结合导致淋巴细胞活化的负调节。
J Exp Med. 2000 Oct 2;192(7):1027-34. doi: 10.1084/jem.192.7.1027.
9
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.通过破坏编码携带免疫受体酪氨酸抑制基序（ITIM）的程序性死亡受体1（PD-1）基因来诱发狼疮样自身免疫性疾病。
Immunity. 1999 Aug;11(2):141-51. doi: 10.1016/s1074-7613(00)80089-8.
10
Enhancement of antitumor immunity by CTLA-4 blockade.通过阻断CTLA-4增强抗肿瘤免疫力。
Science. 1996 Mar 22;271(5256):1734-6. doi: 10.1126/science.271.5256.1734.
Zotero 插件